Disclaimer

The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Annual Report 2023 Download
Sequana Medical is a commercial stage medical device company developing the alfapump® platform for the management of fluid overload in liver disease, malignant ascites and heart failure
Ian Crosbie

Chief Executive Officer

“We are delighted with this successful financing round that is built upon the very encouraging data for both our key programmes that we released recently. With the proceeds from this offering we intend to drive both our North American liver and North American and European heart failure programmes towards important value enhancing events. For POSEIDON, we are planning for the second interim analysis in H1 this year and announcement of the primary endpoint in Q1 2022. Enrolment continues for our RED DESERT study of the alfapump DSR® in heart failure patients and we are very keen to report top-line data expected in H1 2021, with the anticipated start of the SAHARA DESERT feasibility study shortly thereafter. We are grateful for the continuing support of our existing investors, and we are pleased to welcome Optiverder B.V. and new high-quality institutional investors as shareholders on this exciting journey.”

Contact information

Investor Relations:

Email: IR@sequanamedical.com
Tel: +32 498 053579